probucol has been researched along with Blood Clot in 6 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pathogenesis of antiphospholipid antibody (aPL) related thrombosis is multifactorial and includes, amongst others, enhanced coagulation activation measured as prothrombin fragment 1 + 2 (F1 + 2), elevated plasma levels of von Willebrand factor (vWF), plasminogen activator inhibitor (PAI) and endothelin-1 (ET-1) as well as heightened thromboxane generation and lipid peroxidation." | 5.09 | Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. ( Alves, J; Ames, PR; Brancaccio, V; Caccavo, F; Caruso, S; Fossati, G; Iannaccone, L; Morrow, JD; Tommasino, C, 2000) |
| "Polymer-free DESs are as safe and effective as durable polymer DES; however, there is no evidence of any additional benefits provided by this new technology." | 2.50 | Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. ( Angelini, P; Buffon, A; Cortese, B; de Boer, MJ; Dias, S; Kandzari, D; Kelm, M; Kowalewski, M; Kubica, J; Lansky, A; Navarese, EP; Suryapranata, H; Torguson, R; Waksman, R; Wojakowski, W, 2014) |
| "Probucol is a lipid-lowering drug with strong antioxidant properties." | 1.32 | Effects of probucol on endothelial damage by 5-fluorouracil. ( Albertsson, M; Cwikiel, M; Eskilsson, J; Kinhult, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navarese, EP | 1 |
| Kowalewski, M | 1 |
| Cortese, B | 1 |
| Kandzari, D | 1 |
| Dias, S | 1 |
| Wojakowski, W | 1 |
| Buffon, A | 1 |
| Lansky, A | 1 |
| Angelini, P | 1 |
| Torguson, R | 1 |
| Kubica, J | 1 |
| Kelm, M | 1 |
| de Boer, MJ | 1 |
| Waksman, R | 1 |
| Suryapranata, H | 1 |
| Vedantham, K | 1 |
| Chaterji, S | 1 |
| Kim, SW | 1 |
| Park, K | 1 |
| Kinhult, S | 1 |
| Albertsson, M | 1 |
| Eskilsson, J | 1 |
| Cwikiel, M | 1 |
| Tanous, D | 1 |
| Bräsen, JH | 1 |
| Choy, K | 1 |
| Wu, BJ | 1 |
| Kathir, K | 1 |
| Lau, A | 1 |
| Celermajer, DS | 1 |
| Stocker, R | 1 |
| Ames, PR | 1 |
| Tommasino, C | 1 |
| Alves, J | 1 |
| Morrow, JD | 1 |
| Iannaccone, L | 1 |
| Fossati, G | 1 |
| Caruso, S | 1 |
| Caccavo, F | 1 |
| Brancaccio, V | 1 |
| Kisanuki, A | 1 |
| Asada, Y | 1 |
| Hatakeyama, K | 1 |
| Hayashi, T | 1 |
| Sumiyoshi, A | 1 |
1 review available for probucol and Blood Clot
| Article | Year |
|---|---|
Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients.
Topics: Drug-Eluting Stents; Humans; Myocardial Infarction; Polymers; Probucol; Randomized Controlled Trials | 2014 |
1 trial available for probucol and Blood Clot
| Article | Year |
|---|---|
Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study.
Topics: Adult; Albuminuria; Antibodies, Antiphospholipid; Anticholesteremic Agents; Anticoagulants; Antioxid | 2000 |
4 other studies available for probucol and Blood Clot
| Article | Year |
|---|---|
Development of a probucol-releasing antithrombogenic drug eluting stent.
Topics: Aorta; Calorimetry, Differential Scanning; Cell Proliferation; Chemistry, Physical; Drug Delivery Sy | 2012 |
Effects of probucol on endothelial damage by 5-fluorouracil.
Topics: Animals; Anticholesteremic Agents; Antimetabolites, Antineoplastic; Arteries; Endothelium, Vascular; | 2003 |
Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization.
Topics: Animals; Antioxidants; Cell Proliferation; Disease Models, Animal; Follow-Up Studies; Graft Occlusio | 2006 |
Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Hypercholesterolemia; Immunohistoc | 1992 |